尼马瑞韦/利托那韦：真实世界的药物相互作用管理经验。

IF 4.2 2区医学 Q1 INFECTIOUS DISEASES

Expert Review of Anti-infective Therapy Pub Date : 2024-08-22 DOI:10.1080/14787210.2024.2389884

Shahid Bukhari, Stephen Hughes, Nabeela Mughal, Luke S P Moore, Gary Davies, Adrian Vargas Zhang, Megan Ng, Zekiye Karagozlu, Marta Boffito

{"title":"尼马瑞韦/利托那韦：真实世界的药物相互作用管理经验。","authors":"Shahid Bukhari, Stephen Hughes, Nabeela Mughal, Luke S P Moore, Gary Davies, Adrian Vargas Zhang, Megan Ng, Zekiye Karagozlu, Marta Boffito","doi":"10.1080/14787210.2024.2389884","DOIUrl":null,"url":null,"abstract":"Background: In the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions.Research design and methods: We analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.Results: Among 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.Conclusions: This highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nirmatrelvir/ritonavir: real world drug-drug interaction management experience.\",\"authors\":\"Shahid Bukhari, Stephen Hughes, Nabeela Mughal, Luke S P Moore, Gary Davies, Adrian Vargas Zhang, Megan Ng, Zekiye Karagozlu, Marta Boffito\",\"doi\":\"10.1080/14787210.2024.2389884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: In the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions.Research design and methods: We analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.Results: Among 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.Conclusions: This highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.\",\"PeriodicalId\":12213,\"journal\":{\"name\":\"Expert Review of Anti-infective Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2024-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anti-infective Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14787210.2024.2389884\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2389884","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

背景：在英国，COVID-19 药物的区域垂直供应系统已经到位。研究设计和方法：研究设计与方法：我们分析了在一个覆盖 220 万伦敦市民的地理区域内转诊接受尼马瑞韦/利托那韦治疗的成年患者的真实药物相互作用情况：在 208 名接受 NMV/r 治疗的患者中，我们发现了 184 种潜在的 DDI，8% 的患者无法使用 nirmatrelvir/ritonavir，53% 的患者需要接受治疗，但其中 56% 的患者没有接受暂停治疗的建议：结论：这凸显了在 COVID-19 管理中保持和发展临床药理专业知识途径的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nirmatrelvir/ritonavir: real world drug-drug interaction management experience.

Background: In the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions.

Research design and methods: We analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.

Results: Among 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.

Conclusions: This highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Anti-infective Therapy 医学-药学

CiteScore

11.20

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.